The Cystic Fibrosis Foundation is providing additional funding to Arcturus Therapeutics to develop an inhaled messenger RNA therapy for CF that provides lung cells with the correct instructions to make functional cystic fibrosis transmembrane conductance regulator protein. The funding brings our total commitment to Arcturus to approximately $25 million.
Site Search
Centering the patient experience is the only way to successfully reform pharmacy benefit manager practices
Nosis Bio, an inaugural winner of the Foundation’s Golden Ticket Competition, receives funding to further explore design of novel ligands, which are specialized molecules that could help more precise targeting of relevant cells in the lung.
Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science
Human resources veteran Massenburg brings more than 20 years of leadership experience in nonprofit and business sectors
A nonpartisan group of 18 patient, provider, and consumer groups renewed calls for Congress to act on the Bipartisan Health Care Stabilization Act of 2017 in light of Wednesday's Congressional Budget Office (CBO) report.
Medical Experts From 46 Countries to Collaborate at World's Largest Forum on CF Research and Care for Life-Threatening Genetic Disease
2018 Impact Grants provide funding for efforts that support people with cystic fibrosis and their families.
Update: On February 3, 2017, the Cystic Fibrosis Foundation divested its remaining ownership stake in CF Services Inc., a specialty pharmacy. The pharmacy is now fully owned by Walgreens.